Skip to content
The Policy VaultThe Policy Vault

Cordran SP 0.05% creamCigna

symptomatic relief of inflammation and/or pruritus associated with corticosteroid-responsive dermatoses

Preferred products

  • Alclometasone 0.05% ointment/cream
  • Betamethasone dipropionate 0.05% cream/ointment/lotion
  • Betamethasone dipropionate, augmented 0.05% cream/lotion/ointment
  • Betamethasone valerate 0.1% cream/lotion/ointment
  • Clobetasol propionate 0.05% cream/gel/ointment/solution
  • Desonide 0.05% cream/ointment
  • Fluocinolone acetonide 0.01% cream/solution
  • Fluocinolone acetonide 0.025% cream/ointment
  • Fluocinonide 0.05% cream/gel/ointment/solution
  • Fluticasone propionate 0.05% cream/ointment
  • Halobetasol propionate 0.05% cream/ointment
  • Hydrocortisone 1%/2%/2.5%
  • Hydrocortisone butyrate 0.1% emollient cream
  • Hydrocortisone valerate 0.2% cream/ointment
  • Mometasone furoate 0.1% cream/lotion/ointment
  • Prednicarbate 0.1% cream/ointment
  • Triamcinolone acetonide 0.025%/0.1%/0.5% formulations

Initial criteria

  • Patient has tried and failed, or has contraindication/intolerance to TWO Step 1a generic topical corticosteroid products OR Step Therapy rule not met at point of service (as applicable for Step 2a products)
  • Coverage will be granted if Step Therapy criteria are satisfied

Reauthorization criteria

  • Continuation of therapy remains medically necessary as per clinical judgment and benefit plan; no additional step requirement indicated

Approval duration

1 year